Kolon TissueGene, Inc. (KOSDAQ:950160)
South Korea
· Delayed Price · Currency is KRW 106,800
+100 (0.09%)
Apr 29, 2026, 11:00 AM KST
Kolon TissueGene Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 5,159 | 5,073 | 3,706 | 9,456 | 4,003 | Upgrade
|
| Revenue Growth (YoY) | 1.68% | 36.90% | -60.81% | 136.22% | 12.58% | Upgrade
|
| Cost of Revenue | 4,544 | 4,528 | 3,340 | 1,811 | 3,611 | Upgrade
|
| Gross Profit | 614.5 | 545.13 | 365.92 | 7,645 | 392.15 | Upgrade
|
| Selling, General & Admin | 13,343 | 15,849 | 13,679 | 14,694 | 15,906 | Upgrade
|
| Research & Development | 8,549 | 5,612 | 5,635 | 7,123 | 29,890 | Upgrade
|
| Amortization of Goodwill & Intangibles | 29.7 | 39.95 | 113.74 | 98.19 | 87.7 | Upgrade
|
| Other Operating Expenses | 237.61 | 269.39 | 173.93 | 224.81 | 56.02 | Upgrade
|
| Operating Expenses | 22,938 | 22,543 | 20,877 | 23,953 | 47,493 | Upgrade
|
| Operating Income | -22,323 | -21,998 | -20,511 | -16,308 | -47,101 | Upgrade
|
| Interest Expense | -89.6 | -89.85 | -285.82 | -371.18 | -466.46 | Upgrade
|
| Interest & Investment Income | 1,760 | 1,040 | 2,221 | 670.49 | 129.69 | Upgrade
|
| Currency Exchange Gain (Loss) | 787.43 | 813.15 | 256.82 | 1,512 | 50.89 | Upgrade
|
| Other Non Operating Income (Expenses) | -172,739 | -13,661 | 1,351 | 4,676 | 249.99 | Upgrade
|
| EBT Excluding Unusual Items | -192,604 | -33,895 | -16,968 | -9,821 | -47,136 | Upgrade
|
| Gain (Loss) on Sale of Assets | 37.35 | 1.02 | -3.43 | - | -14.87 | Upgrade
|
| Pretax Income | -192,567 | -33,894 | -16,971 | -9,821 | -47,151 | Upgrade
|
| Income Tax Expense | 20.94 | -95.47 | 253.15 | 1,316 | 218.27 | Upgrade
|
| Net Income | -192,587 | -33,799 | -17,224 | -11,136 | -47,370 | Upgrade
|
| Net Income to Common | -192,587 | -33,799 | -17,224 | -11,136 | -47,370 | Upgrade
|
| Shares Outstanding (Basic) | 82 | 77 | 72 | 66 | 61 | Upgrade
|
| Shares Outstanding (Diluted) | 82 | 77 | 72 | 66 | 61 | Upgrade
|
| Shares Change (YoY) | 6.78% | 7.32% | 8.18% | 8.25% | 0.29% | Upgrade
|
| EPS (Basic) | -2343.80 | -439.20 | -240.20 | -168.00 | -773.60 | Upgrade
|
| EPS (Diluted) | -2343.80 | -439.20 | -240.20 | -168.00 | -773.60 | Upgrade
|
| Free Cash Flow | -25,210 | -20,581 | -24,370 | -26,844 | -40,568 | Upgrade
|
| Free Cash Flow Per Share | -306.81 | -267.44 | -339.84 | -404.97 | -662.52 | Upgrade
|
| Gross Margin | 11.91% | 10.75% | 9.87% | 80.85% | 9.80% | Upgrade
|
| Operating Margin | -432.73% | -433.58% | -553.45% | -172.46% | -1176.59% | Upgrade
|
| Profit Margin | -3733.25% | -666.19% | -464.76% | -117.77% | -1183.31% | Upgrade
|
| Free Cash Flow Margin | -488.69% | -405.66% | -657.56% | -283.88% | -1013.40% | Upgrade
|
| EBITDA | -21,539 | -21,189 | -19,099 | -14,643 | -45,550 | Upgrade
|
| EBITDA Margin | - | - | - | -154.85% | - | Upgrade
|
| D&A For EBITDA | 784.02 | 808.55 | 1,412 | 1,665 | 1,551 | Upgrade
|
| EBIT | -22,323 | -21,998 | -20,511 | -16,308 | -47,101 | Upgrade
|
| EBIT Margin | - | - | - | -172.46% | - | Upgrade
|
| Advertising Expenses | 19.35 | 37.32 | 11.48 | 0.5 | 18.66 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.